Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Shandong Xinhua Pharmaceutical Company Limited Class H ( (HK:0719) ) has issued an announcement.
Shandong Xinhua Pharmaceutical Company Limited has received approval from the National Medical Products Administration for the change of marketing license holder for its Eszolam tablets. This approval follows a contract signed with Guangxi Dahai Sunshine Pharmaceutical Company Limited for the transfer of the Marketing Authorization Holder status and related technical ownership rights, marking a significant step in the company’s strategic operations.
More about Shandong Xinhua Pharmaceutical Company Limited Class H
Shandong Xinhua Pharmaceutical Company Limited is a pharmaceutical company based in China, focusing on the production and marketing of prescription drugs. The company is involved in the development and commercialization of various pharmaceutical products, with a particular emphasis on prescription medications.
YTD Price Performance: -7.75%
Average Trading Volume: 2,131,863
Technical Sentiment Signal: Hold
Current Market Cap: HK$8.24B
For an in-depth examination of 0719 stock, go to TipRanks’ Stock Analysis page.